However, the combined CpG-STAT3ASO/anti-PD-1 treatment and to a lesser extent CpG-STAT3ASO alone strongly increased the recruitment of activated, antigen-presenting MHC-IIHI/CD86+ macrophages (Figure 7C) and DCs (Figure 7D and Supplementary Figure S5) into tumor-draining lymph nodes. The gene discussed is CD86; the disease is neoplasm.